重症社区获得性肺炎常见病原菌抗感染治疗最新研究进展  

Recent Research Progress in Anti-Infective Treatment of Common Pathogens of Severe Community-Acquired Pneumonia

作　　者：冯金柯 何五建 

机构地区：[1]青海大学研究生院临床医学系,青海 西宁

出　　处：《临床个性化医学》2024年第2期374-379,共6页Journal of Clinical Personalized Medicine

摘　　要：重症社区获得性肺炎(SCAP)仍然是全球重要的致病和死亡原因,特别是在严重病例中。了解导致SCAP的病原菌对于选择适当的治疗至关重要。本综述总结了与SCAP相关的常见病原菌治疗方面的最新进展,包括细菌、病毒和真菌病因。它审视了抗微生物药物耐药性的发展态势,并讨论了最佳治疗策略,包括抗生素物选择、联合治疗和辅助治疗。此外,本综述强调了基于患者个体差异和不同地区流行病学的个体化治疗方法对于改善SCAP管理的结果至关重要。Severe community-acquired pneumonia (SCAP) remains a significant cause of morbidity and mortality globally, particularly in severe cases. Understanding the pathogens leading to SCAP is crucial for selecting appropriate treatment. This review summarizes the latest developments in the treatment of common pathogens associated with SCAP, including bacterial, viral, and fungal etiologies. It examines the evolving trends in antimicrobial drug resistance and discusses optimal treatment strategies, including antibiotic selection, combination therapy, and adjunctive therapy. Additionally, the review emphasizes the importance of personalized treatment approaches based on individual patient differences and regional epidemiology in improving outcomes in SCAP management.

关 键 词：重症社区获得性肺炎 肺炎链球菌 流感嗜血杆菌 金黄色葡萄球菌 多重耐药菌 

分 类 号：R56[医药卫生—呼吸系统]